Eprex
Eprex 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为MDS、Myelodysplastic Syndromes。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
7 项
已进入 III/IV 期
35 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Groupe Francophone des Myelodysplasies
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- National Cancer Institute (NCI)
- Australian and New Zealand Intensive Care Research Centre
- Alexandria University
- Zealand University Hospital
- Mansoura University
- Piotr Czempik
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
意大利、美国、加拿大、Puerto Rico、澳大利亚、比利时、芬兰、德国、爱尔兰、新西兰、Saudi Arabia、Slovenia
正在招募患者的 Eprex 研究
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
不适用招募中意大利NCT05931718MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
II 期招募中美国加拿大Puerto RicoNCT05564390ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients
III 期招募中澳大利亚比利时芬兰德国NCT04588311Erythropoietin - Albumin Platelet-rich Fibrin in Transcrestal Sinus Lifting With Simultaneous Implant Placement
不适用招募中EgyptNCT07150858The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp
不适用招募中丹麦NCT04330729Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients
I 期 / II 期招募中EgyptNCT06917950Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial
IV 期招募中PolandNCT06670963EVR and EPO for Liver Transplant Tolerance
I 期招募中美国NCT06832189Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)
III 期招募中西班牙NCT07169643Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
I 期 / II 期招募中法国意大利NCT05181735Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
I 期 / II 期招募中EgyptNCT06903559The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
不适用招募中中国NCT06012760A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
III 期招募中美国Argentina澳大利亚比利时NCT07422480Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
不适用招募中IndiaNCT07002827Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome
不适用招募中意大利NCT06764511Effect of the Combined Programme on Perioperative Anaemia（CPPA）
不适用招募中中国NCT05353348Erythropoietin Gel Effect on Dental Implant Stability
不适用招募中EgyptNCT06665451Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis
IV 期招募中中国NCT07045155A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
III 期招募中ArmeniaBulgariaCzechiaGeorgiaNCT06466785Peripheral Serotonin and Albinism
不适用招募中法国NCT06138509Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy
不适用招募中中国NCT06968936Combination Therapy of Romiplostim and Erythropoiesis-stimulating Agents
II 期招募中中国香港NCT07854561PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).
III 期招募中BangladeshNCT07025681Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage
I 期招募中美国NCT05617833
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。